Esperion Therapeutics Inc. [ESPR] stock is trading at $2.34, up 5.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The ESPR shares have gain 7.34% over the last week, with a monthly amount glided 2.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Esperion Therapeutics Inc. [NASDAQ: ESPR] stock has seen the most recent analyst activity on June 20, 2024, when BofA Securities downgraded its rating to a Underperform but kept the price target unchanged to $2.50 for it. Previously, BofA Securities downgraded its rating to Neutral on January 03, 2024. Northland Capital upgraded its rating to a Market Perform. BofA Securities upgraded its rating to a Buy and raised its price target to $4 on June 15, 2023. Northland Capital downgraded its rating to Under Perform for this stock on March 16, 2023, but kept the price target unchanged to $1. In a note dated March 16, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $8 to $1.50.
Esperion Therapeutics Inc. [ESPR] stock has fluctuated between $0.70 and $3.40 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Esperion Therapeutics Inc. [NASDAQ: ESPR] shares were valued at $2.34 at the most recent close of the market. An investor can expect a potential return of 583.76% based on the average ESPR price forecast.
Analyzing the ESPR fundamentals
Esperion Therapeutics Inc. [NASDAQ:ESPR] reported sales of 229.74M for the trailing twelve months, which represents a growth of 466.14%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -0.15%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is 0.23 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.85.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.21 points at the first support level, and at 2.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.49, and for the 2nd resistance point, it is at 2.63.
Ratios To Look Out For
For context, Esperion Therapeutics Inc.’s Current Ratio is 2.22. On the other hand, the Quick Ratio is 1.78, and the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 1.74.
Transactions by insiders
Recent insider trading involved Foody Joanne M., Chief Medical Officer, that happened on Jun 18 ’24 when 3285.0 shares were sold. Chief Commercial Officer, Warren Eric completed a deal on Jun 18 ’24 to sell 2540.0 shares. Meanwhile, Chief Commercial Officer Warren Eric sold 192.0 shares on May 17 ’24.
